Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06108050 · ClinicalTrials.gov registry record · Phase 1
JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors
A Phase 1 study of Advanced Solid Tumor and Metastatic Solid Tumor, sponsored by Jazz Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 177
- Enrollment target
- 10
- Study locations
NCT06108050: Recruiting Phase 1 study of Advanced Solid Tumor and Metastatic Solid Tumor, sponsored by Jazz Pharmaceuticals.
NCT06108050 is a Phase 1 study of Advanced Solid Tumor and Metastatic Solid Tumor that is actively recruiting participants, run by Jazz Pharmaceuticals. The registered enrollment target is 177 participants, roughly in line with the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target. The trial reports 10 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06108050, a Phase 1 study of Advanced Solid Tumor and Metastatic Solid Tumor, is actively recruiting participants, sponsored by Jazz Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 177 participants
- Enrollment target
- 10
- Study locations
Study Summary
This Phase 1 first-in-human study will investigate the safety, tolerability, pharmacokinetics (PK), immunogenicity, and preliminary antitumor activity of JZP898 monotherapy as well as JZP898 in combination with pembrolizumab in adult participants with advanced or metastatic solid tumors.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG JZP898
Study Locations (10)
California
- California Cancer Associates for Research and Excellence - Encinitas
- California Cancer Associates for Research and Excellence - Fresno
Texas
- Texas Oncology - Baylor Charles A Sammons Cancer Center - Dallas
- The University of Texas MD Anderson Cancer Center - Houston
Colorado
- Sarah Cannon Research Institute at HealthONE - Denver
Florida
- Florida Cancer Specialists - Orlando
North Carolina
- Duke University Medical Center - Duke Cancer Institute - Durham
Pennsylvania
- Sidney Kimmel Cancer Center at Thomas Jefferson University Hospital - Philadelphia
Tennessee
- SCRI Oncology Partners - Nashville
Virginia
- Virginia Cancer Specialists - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 177 participants |
| Start Date | 2023-11-07 |
| Est. Completion | 2028-05-31 |
| Phase | Phase 1 |
What NCT06108050 shows while recruiting
NCT06108050 is an interventional study that assigns participants to a tested intervention. The registered 177 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target.
The record links to 2 conditions, with Advanced Solid Tumor appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT06108050 lists 10 locations in 8 states (California, Texas, Colorado).
Frequently Asked Questions
What is clinical trial NCT06108050 about?
NCT06108050 is a clinical study titled "JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors". This Phase 1 first-in-human study will investigate the safety, tolerability, pharmacokinetics (PK), immunogenicity, and preliminary antitumor activity of JZP898 monotherapy as well as JZP898 in combination with pembrolizumab in adult participants with advanced or metastatic solid tumors.
What is the current status of trial NCT06108050?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 177 participants. The study started on 2023-11-07. Estimated completion is 2028-05-31.
What conditions does trial NCT06108050 study?
This clinical trial studies the following conditions: Advanced Solid Tumor, Metastatic Solid Tumor.
What interventions are being tested in trial NCT06108050?
The interventions under investigation include: Pembrolizumab (DRUG), JZP898 (DRUG).
Who is sponsoring clinical trial NCT06108050?
This trial is sponsored by Jazz Pharmaceuticals, which has 128 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06108050 being conducted?
This trial has 10 study locations across California, Colorado, Florida, North Carolina, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06108050's enrollment target sits among peer trials
177 73rd of 189 higher than 117 of 189 other Advanced Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
PM14 Administered Intravenously to Patients with Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of EP0031 in Patients With Advanced RET-altered Malignancies
RECRUITING · Phase 1
-
Study of AVZO-021 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05491551 · 177 participants · NA
Alcohol-ROC-Training
- NCT06575712 · 177 participants · NA
Coping Skills Training for Symptom Management and Daily Steps (Step Up)
- NCT06674980 · 177 participants · NA
Clinical Trial Assessing Human Placental Membrane Products and Standard of Care Versus Standard of Care in Nonhealing DFUs and VLUs
- NCT06719011 · 177 participants · Phase 1
A Study on How NNC0174-1213 Works in People With Overweight or Obesity.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI